[PARP Inhibitors: From the Mechanism of Action to Clinical Practice]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• DNA damage repair is vital for genome integrity and preventing cancer.
• Poly (ADP-ribose) polymerases (PARP) enzymes are critical in DNA error signaling and repair.
• PARP inhibitors exploit synthetic lethality for treating cancers with DNA repair defects, particularly BRCA1/BRCA2 mutations.

Purpose of the Study:

• To provide an updated review of PARP inhibitors (iPARP) in cancer treatment.
• To highlight the role of iPARP in tumor cells.
• To discuss emerging resistance mechanisms, clinical applications, and toxicity of iPARP.

Main Methods:

• Literature review of scientific articles and clinical trial data.
• Analysis of molecular mechanisms underlying PARP inhibitor activity and resistance.
• Synthesis of information on current clinical applications and toxicological profiles.

Main Results:

• PARP inhibitors are approved for treating breast, ovarian, pancreatic, and prostate cancers with specific DNA repair defects.
• Resistance to iPARP is a significant clinical challenge, developing through diverse molecular pathways.
• Understanding these resistance mechanisms is key to improving therapeutic outcomes.

Conclusions:

• PARP inhibitors represent a significant advancement in targeted cancer therapy.
• Addressing iPARP resistance is crucial for optimizing treatment efficacy.
• Continued research is needed to overcome resistance and expand the clinical utility of PARP inhibitors.